Herlev Hospital — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

10 Registered trials

4 Recruiting

4 Completed trials

1 Countries active

10 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase I

Oversight events:

1 serious breach across 1 trial

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

10 total

CRISPR-TIL for metastatic melanoma Not authorised

2023-510417-25-00 Phase I 1 country
The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia Pending

2025-524774-42-00 Phase II 1 country LEFLUTROZOLE
CRISPR-TIL for metastatic melanoma Recruiting

2023-510417-25-01 Phase I 1 country
The LIFE-MET Study: Lifestyle intervention and Metformin in early puberty. Recruiting

2024-511009-50-00 Phase II 1 country METFORMIN HYDROCHLORIDE
ADP-TILIL7 Recruiting

2023-509665-20-00 Phase I 1 country
Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease Recruiting

2023-506853-39-00 Phase IV 1 country
Early versus postponed supplementary parenteral nutrition after major emergency abdominal surgery Ended

2023-505378-14-00 Phase IV 1 country VALINE, ALANINE, ARGININE, HISTIDINE, ISOLEUCINE, LEUCINE, METHIONINE, PHENYLALA…
NAPO - Novel Approach for Oligospermia Ended

2023-508325-27-00 Phase II 1 country DENOSUMAB
Efficacy of Remimazolam with Fentanyl versus Midazolam with Fentanyl Ended

2023-503470-21-00 Phase IV 1 country FENTANYL CITRATE; MIDAZOLAM HYDROCHLORIDE; REMIMAZOLAM
Oral antibiotics to prevent infection and wound dehiscence after obstetric perineal tear Ended

2022-501930-49-00 Phase IV 1 country AMOXICILLIN, CLAVULANIC ACID

Showing 1–10 of 10 trials